Phrontline Biopharma

Phrontline Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing innovative antibody-drug conjugates to address unmet medical needs in oncology. The company specializes in engineering bispecific dual-payload ADCs, utilizing proprietary technology platforms to enhance the precision and efficiency... of therapeutic delivery. Phrontline Biopharma focuses on optimizing dual targeting to increase patient coverage and improve tumor cell internalization, while employing dual payloads to overcome drug resistance, tumor heterogeneity, and enhance durability of response. The company's approach aims to address the limitations of traditional single-payload, single-target ADCs by delivering two different mechanisms of action payloads to cancer cells simultaneously. Phrontline Biopharma operates through integrated technology platforms including its SynTume and 2by2 ADC systems, advancing multiple preclinical and clinical programs targeting various solid tumors. The company has established strategic partnerships with major pharmaceutical companies to co-develop investigational ADC assets directed against targets expressed in a broad range of cancers, including EGFR and HER3. Founded in 2022, Phrontline Biopharma is committed to advancing more effective and durable treatment options for patients with high unmet medical needs through in-house innovation.Read More